

Article

Impact of SchisandraChinensis Bee Pollen on Nonalcoholic Fatty Liver Disease and Gut Microbiota in HighFat Diet Induced Obese Mice

Ni Cheng ^{1,3,*}, Sinan Chen ¹ , Xinyan Liu ¹, Haoan Zhao ²  and Wei Cao ^{1,3,*}

¹ College of Food Science and Technology, Northwest University, 229 North TaiBai Road, Xi'an 710069, China; chensinan111@163.com (S.C.); liuxinyan946926@163.com (X.L.)

² School of Chemical Engineering, Northwest University, 229 North TaiBai Road, Xi'an 710069, China; haoan_zhao@126.com

³ Bee Product Research Center of Shaanxi Province, Xi'an 710065, China

* Correspondence: chengni@nwu.edu.cn (N.C.); caowei@nwu.edu.cn (W.C.); Tel./Fax: +86-29-8830-2213 (N.C. & W.C.).

Received: 8 November 2018; Accepted: 31 January 2019; Published: 6 February 2019



Abstract: *Schisandrachinensis*bee pollen has been used as a health food in China for centuries; however, its bioactive constituents and functions are not very clear. In this study, we investigated the phenolic compounds of *Schisandrachinensis*bee pollen extract (SCPE) by UHPLC-Q-Orbitrap-HRMS/HPLC-DAD-ECD and its prevention from nonalcoholic fatty liver disease (NAFLD) and modulation of gut microbiota in high fat diet induced obese C57BL/6 mice. The results showed that 12 phenolic compounds were identified in SCPE, and naringenin, rutin and chrysin were the main constituents. The content of naringenin reached 1.89 mg/g, and total phenolic content (TPC) of SCPE were 101.83 mg GA/g. After obese mice were administrated with SCPE at 7.86 and 15.72 g/kg BW for 8 weeks, body weight gains were reduced by 18.23% and 19.37%. SCPE could decrease fasting blood glucose, cut down the lipid accumulation in serum and liver, lessen oxidative injury and inflammation in obesity mice. Moreover, SCPE could effectively inhibit the formation of NAFLD by inhibition of LXR- α , SREBP-1c and FAS genes expression, and modulate the structural alteration of gut microbiota in obesity mice. These findings suggested that SCPE could attenuate the features of the metabolism syndrome in obesity mice, which can be used to prevent obesity and NAFLD of human beings.

Keywords: *Schisandrachinensis*bee pollen; gut microbiota; nonalcoholic fatty liver disease; obesity; phenolic compounds

1. Introduction

Obesity is a growing serious public health problem in China and worldwide associated with chronic metabolic diseases such as type 2 diabetes, coronary artery disease, hypertension, hyperlipidemia, nonalcoholic fatty liver disease (NAFLD), and even cancers in China and all over the world [1–3]. Recent reviews have demonstrated that a growing number of children and adolescents suffer from overweight and obesity, seriously affecting their physical and intellectual development [4–6]. NAFLD is a common disease induced by obesity in children and adolescents [7], accompanied by excessive fat deposition in hepatocytes in the absence of significant alcohol consumption [8]. Dietary fat, especially saturated fatty acids, should be one of the important factors in the development of NAFLD [9]. Usually, NAFLD accompanied with inflammation, fibrosis and malignant transformation was difficult to diagnose in the early stage [10]. Therefore, prevention and dietary intervention are becoming increasingly important in people's daily lives.

Phenolic compounds are a large group of plant secondary metabolites, which possess the capabilities of antioxidant, anti-inflammation, antitumor, antihypertensive, and prevention of the diseases induced by oxidative stress [11]. Recent studies have reported that phenolic compounds can reach the colon, be utilized by gut microbiota, and take part in nutrient acquisition and lipid metabolism, playing a critical role in metabolic diseases [12,13]. Tea polyphenols could modulate gut dysbiosis induced by high-fat diet and cause weight loss in mice [14–16]. Polyphenol-rich extract of pomegranate peel consumption regulated gut microbiota and then alleviated tissue inflammation and hypercholesterolaemia in obese mice [17]. Grape polyphenolic consumption altered gut microbiota and reduced adiposity [18]. Lychee pulp polyphenols reduced the body weight and ameliorate hepatic lipid accumulation in obese mice induced by high-fat diet [19]. However, there has been no research on the anti-obesity effect and prevention from NAFLD of bee pollen polyphenols conducted to date.

Schisandrachinensis bee pollen collected by honey bees from the flowers of *S. chinensis* is a widely cultivated plant in China and has been used as medicine to treat liver disease for several centuries. In our previous study, healthy protection of *S. chinensis* bee pollen has been studied, the result elucidated that *S. chinensis* pollen possessed strong antioxidant activities and prevented liver damage induced by CCl₄. However, there has been no research on the relationship of *S. chinensis* pollen and obesity, NAFLD. In this study, we investigated the phenolic compounds of *S. chinensis* pollen extracted (SCPE) by UHPLC-Q-Orbitrap-HRMS/HPLC-DAD-ECD, and its antioxidant activities in vitro. More importantly, administration with SCPE preventing NAFLD and gut microbiota disorder induced by high-fat diet in mice were studied in this report, providing a theoretical reference for the biological function of *S. chinensis* bee pollen.

2. Materials and Methods

2.1. Preparation and Identification of SCPE

Bee pollen of *S. chinensis* was purchased from Hubei province. Its floral origin was identified by comparison with pollen morphology of *S. chinensis* reported by Ai et al. [20] and Sun [21]. The sample was extracted twice with 10 times 75% (*v/v*) ethanol under heat reflux for 2 h at 75 °C. The supernatant was collected by centrifugation at 4800 rpm for 10 min and concentrated under vacuum to give the *S. chinensis* pollen extract (SCPE).

UHPLC-Q-Orbitrap-HRMS analysis of SCPE was performed using a UHPLC system (1290, Agilent Technologies) with UPLC HSS T3 column (2.1 mm × 100 mm, 1.8 μm) coupled to Q Exactive (Orbitrap MS, Thermo). The mobile phase A was 5 mmol/L ammonium acetate in water for negative, and the mobile phase B was acetonitrile. The elution gradient was set as follows: 0 min, 1% B; 1 min, 1% B; 8 min, 99% B; 10 min, 99% B; 10.1 min, 1% B; 12 min, 1% B. The flow rate was 0.5 mL/min. The injection volume was 1 μL. MS data were executed in negative ion mode because of one or more carboxylic acid or hydroxyl groups containing in polyphenols. HPLC-DAD-ECD (U3000, Thermo Fisher) was used in the quantitative analysis of the phenolic compounds in SCPE. All the standards of phenolic compounds in this study were chromatographic grade and purchased from Sigma-Aldrich (USA). Due to the complexity of polyphenols in SCPE, total phenolic content (TPC) and total flavonoid content (TFC) were also determined by the methods used in our previous study [22]. The result of TPC was calculated with the gallic acid equivalents (mg GA/g SCPE) and TFC was calculated with rutin equivalents (mg rutin/g SCPE) respectively.

2.2. Antioxidant Activities of SCPE

DPPH radical scavenging activity was measured according to the method proposed by Brand-Williams (1995) [23]. Briefly, different volumes of SCPE solution at 1.0 mg/mL were mixed with 5.0 mL of a methanolic solution of DPPH radicals at 0.1 mM in brown test tubes. The total volume was adjusted to 10 mL with methanol, and then shaken evenly. It was stand at room temperature in

the dark for 30 min. Absorbance was measured at 517 nm. The result was expressed as IC₅₀ value (the concentration of SCPE required to reach the inhibition of DPPH radicals to 50%).

Ferric reducing antioxidant power (FRAP) of SCPE was determined according to a modified method [24]. SCPE solution was mixed with 4.0 mL of FRAP reagent (2.5 mL of 20 mM FeCl₃·6H₂O and 25 mL of 0.3 M acetate buffer, pH 3.6). The absorbance was measured at 593 nm and the result was expressed as Trolox equivalent (mg Trolox/g SCPE).

Ferrous ion-chelating activity of SCPE was carried out by the method proposed by Singh and Rajini [25]. The absorbance of ferrozine-Fe²⁺ complex was determined at 562 nm. Ferrous ion-chelating activity was expressed as Na₂EDTA equivalents (mg Na₂EDTA/g SCPE).

2.3. Animal Experiments

Forty-eight male C57BL/6 mice (16–18 g) were obtained from laboratory animal research center of Fourth Military Medical University (Xi'an, Shaanxi, China), and the license number was SCXK (Army) 2012-007. All mice were raised under standard laboratory conditions (temperature 25 ± 2 °C, relative humidity 50 ± 10%, under 12 h light-dark cycles). After acclimation for 1 week, the mice were divided into four groups, randomly. One group was provided with a low-fat diet (LFD, 8% fat, 22% proteins, 70% carbohydrates), which supplied 3.4 kcal/g energy. The other three groups were provided with a high-fat diet (HFD, 45% fat, 18% proteins, 37% carbohydrates), which supplied 5.2 kcal/g energy. LFD and HFD were provided until the end of the experiment. All the feed was purchased from Shanghai Fanbo Biotechnology Co., Ltd. (Shanghai, China). Eight weeks later, two of the HFD groups were respectively given 7.86 and 15.72 g SCPE/kg BW by intragastric administration for the following 8 weeks. The four groups in this study were expressed as LFD, HFD, HFD + LE (7.86 g/kg BW) and HFD + HE (15.72 g/kg BW) groups, respectively.

Fasting body weight was obtained every two weeks. At the end of 16th week, all the mice were fasted for 10 h and then blood samples were obtained by cardiac puncture. A drop of blood was used for blood-glucose testing by a blood glucose meter (Yicheng Bioelectronics Technology Co., Ltd., Beijing, China). After killing the mice by cervical dislocation, liver, spleen, colon, and epididymal adipose were separated and the liver and spleen were weighed out immediately.

2.4. Serum and Hepatic Biochemical Analysis

The serum samples were analyzed for total cholesterol (TC), triglyceride (TG), LDL-cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST) using commercially available diagnostic kits produced by Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Serum interleukin-6 (IL-6), tumor necrosis factor α (TNF- α) were characterized by immunoassay using commercial ELISA kits produced by Shanghai Fusheng Industrial Co., Ltd. (Shanghai, China). All the test procedures were carried out according to the manufacturer's instructions.

A part of the liver was homogenized in 9 volumes of ice-cold physiological saline, centrifuged at 2500 rpm for 15 min at 4 °C. The supernatant was used for following analysis. Diagnostic kits from Nanjing Jiancheng Bioengineering Institute (Nanjing, China) were used in the determination of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, and the ELISA kit for adiponectin purchased from Shanghai Fusheng Industrial Co., Ltd. (Shanghai, China) was used for quantifying the adiponectin in liver. The results were normalized with protein. In addition, anhydrous alcohol served as the homogenate medium and the supernatant was used for determination the content of TG and TC. The results expressed as the content per liter supernatant (mmol/L).

2.5. Quantification of Gene Expression Analysis

Total RNA from liver was extracted using a Takara minibest universal RNA extraction kit (Takara, Dalian, China) according to the manufacturer's instructions. RNA was reverse-transcribed using PrimescriptTM rt master mix kit (Takara, Dalian, China). The cDNA samples were amplified in duplicate. Quantitative real-time PCR (Q-PCR) was performed on the Real Time PCR amplification instrument

(Gentier 96E, Xi'an Tianlong Science and Technology Co., China) with TB Green™ Premix Ex Taq™ II. The Q-PCR conditions were as follows: 95 °C, 30 s, followed by 40 cycles at 95 °C, 5 s, 60 °C, 30 s. The primer sequences of interleukin -1 β (IL-1 β), TNF- α , nuclear factor κ B (NF- κ B), inducible nitric oxide synthase (iNOS) and β -actin were designed according to the method proposed by Wu et al. (2015) [26]. The primer sequences of fatty liver related genes such as liver X receptors (LXR)- α , sterol regulatory element binding protein (SREBP)-1c and fatty acid synthase (FAS) were designed according to the study of Sim et al. (2014) [27]. Purity of PCR products was assessed by melt curve analysis. Gene expression was examined and normalized with β -actin, which served as an internal control in PCR, and the relative fold induction was calculated using the formula $2^{-\Delta\Delta C_t}$ [28].

2.6. Histopathological Examinations of Liver and Epididymal Adipose

For the histological evaluation, a portion of liver and epididymal adipose were fixed in 10% neutral formalin and embedded in paraffin wax. Sections of 5 μ m thickness were cut, deparaffinized, dehydrated, and then stained with hematoxylin and eosin (H&E).

2.7. Illumina Sequencing and Statistical Analysis of 16S rRNA Gene V3-V4 Region of Gut Microbiota

Total genomic DNA was extracted from colon contents using the Fast SPIN extraction kits (MP Biomedicals, Santa Ana, CA, USA), according to the manufacturer's instructions. The quantity and quality of extracted DNA were measured using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and agarose gel electrophoresis, respectively. PCR amplification of the bacterial 16S rRNA genes V3-V4 hypervariable regions was performed using the forward primer 338F (5'-ACTCCTACGGGAGGCAGCA-3') and the reverse primer 806R (5'-GGACTACHVGGGTWTCTAAT-3') according to the method proposed by Liu et al. (2018) [29]. PCR amplicons were purified with AgencourtAMPure Beads (Beckman Coulter, Indianapolis, IN) and quantified using the PicoGreendsDNA Assay Kit (Invitrogen, Carlsbad, CA, USA). After the individual quantification step, amplicons were pooled in equal amounts, and pair-end 2 $\times$ 300 bp sequencing was performed using the IlluminaMiSeq platform with MiSeq Reagent Kit v3 at Shanghai PersonalBiotechnology Co., Ltd (Shanghai, China).

The quantitative insights into microbial ecology (QIIME, v1.8.0) pipeline was employed to process the sequencing data according to the method proposed by Caporaso et al. (2010) [30]. The operational taxonomy units (OTUs) of representative sequences at 97% similarity and their relative abundance were used to calculate rarefaction analysis and Shannon diversity index by UCLUST. Nonmetric multidimensional scaling (NMDS) were used to examine the abundance and diversity of the OTUs.

2.8. Statistical Analysis

All the tests were performed in triplicate. Statistically significant differences were evaluated by Duncan's multiple range test after SAS one-way ANOVA, version 8.1 (SAS Institute, Cary, NC, USA). Differences at $p < 0.05$ were considered to be significant.

3. Results

3.1. The Phenolic Compound and Antioxidant Activity of SCPE

Twelve phenolic compounds were identified in SCPE by UHPLC-Q-Orbitrap-HRMS based on accurate comparison of experimental ions, calculated ions, and fragment ions. Seven phenolic compounds were quantified by HPLC-DAD-ECD, and the results are shown in Table 1. Naringenin was the most abundant compound in the quantified phenolics, reaching 1.89 mg/g. Rutin and chrysin were more than 0.5 mg/g in SCPE. The structural formulas of all identified phenolic compounds are shown in the supporting information Figure S1.

The TPC, TFC and antioxidant activity in vitro of SCPE are displayed in Table 2. The TPC and TFC were 101.83 mg GA/g and 73.22 mg rutin/g, respectively. DPPH scavenging activity (IC_{50}) was 0.74 mg/mL. The FRAP value was 297.80 mg Trolox/g. Ferrous ion-chelating activity was 44.82 mg Na_2EDTA /g.

Table 1. Characterization of the 12 compounds of SCPE by UHPLC-Q-Orbitrap-HRMS.

No.	Compounds	t_R (min)	Exptl (m/z)	Calcd (m/z)	Fragment Ions (m/z)	Content (mg/g)
1	2,3-Dihydroxybenzoic acid	2.26	153.0193	153.0193	135.0 (5), 117.0 (10), 109.0 (10), 91 (5), 73.0 (5)	0.0111
2	4-Hydroxybenzoic acid	2.72	137.0244	137.0244	119.0 (50), 93.0 (10), 75.0 (5)	-
3	2,4-Dihydroxybenzoic Acid	3.20	153.0193	153.0193	135.0 (50), 117.0 (10), 109.0 (50), 91 (5), 73.0 (5)	0.0673
4	5-Methoxysalicylic acid	3.28	167.0349	167.035	149.0 (20), 123.0 (10)	0.0176
5	Rutin	3.49	609.1462	609.1461	301.0 (100)	0.5375
6	Kaempferol 3-O- β -rutoside	3.62	593.1512	593.1512	285.0 (10)	-
7	Quercetin 3- β -D-glucoside	3.65	463.0883	463.0882	301.1 (10), 179.1 (10)	-
8	4-Hydroxycoumarin	3.90	161.0245	161.0244	143.0 (40), 133.0 (10), 117.0 (20), 115.0 (5), 99.0 (5)	-
9	Naringenin	4.84	271.0612	271.0612	271.1 (40), 165.0 (40)	1.8934
10	Apigenin	4.88	269.0455	269.0455	151.0 (15)	-
11	Chrysin	5.73	253.0506	253.0506	151.1 (25)	0.5627
12	Isoliquiritigenin	5.77	255.0663	255.0663	119.0 (20)	0.2830

Table 2. The result of TPC, TFC and antioxidant activities of SCPE in vitro.

TPC (mg GA/g)	TFC (mg rutin/g)	DPPH Scavenging Activity IC_{50} (mg/mL)	FRAP (mg Trolox/g)	Ferrous Ion-Chelating Activity (mg Na_2EDTA /g)
101.83 $\pm$ 0.01	73.22 $\pm$ 0.04	0.74 $\pm$ 0.05	297.80 $\pm$ 0.92	44.82 $\pm$ 0.60

Results presented in the table are expressed as mean $\pm$ standard deviation (SD) for 3 replications.

3.2. SCPE Attenuated Obesity Induced by HFD in Mice

Obesity and type 2 diabetes are the two major risk factors for NAFLD; therefore, body weight, liver weight and fasting blood glucose were determined in this study and the results were shown in Figure 1. The mice were weighed every two weeks during the experiment. At the end of 8th week, the weight of the mice with HFD reached 33.94 g, which was an increase of 31.50% in comparison to the LFD group. After administration with SCPE at a dose of 7.86 and 15.72 g/kg BW, the body weight declined by 18.23% and 19.37% over the HFD group, respectively. The liver weight of the HFD group was significantly higher than LFD group ($p < 0.05$). Excitingly, SCPE consumption completely inhibited the increase of liver weight induced by HFD. Similarly, the increase of fasting blood glucose induced by HFD was ameliorated by SCPE administration. There was no significant difference in spleen weights among all mice.




Figure 1. Effects of SCPE on fasting body weight (A), liver weight (B), spleen weight (C) and fasting blood glucose (D) of mice. Different lower-case letters correspond to significant differences at $p < 0.05$.

3.3. Effects of SCPE on TC, TG and LDL-C Levels in Serum and Liver

As shown in Figure 2A,B, a 201% increase of TC level and a 45.1% increase of TG level in serum was observed in the HFD group. Treatment with SCPE did not decrease the content of TC in serum. However, SCPE administration in different dosages could significantly decrease the content of TG in serum ($p < 0.05$). Although HFD did not increase serum LDL-C level, SCPE consumption decreased serum LDL-C level compared to the HFD group ($p < 0.05$).

The contents of TC and TG in the liver were significantly increased by HFD feeding ($p < 0.05$) (Figure 2C). A 74.1% increase of TC content and a 107% increase of TG content in liver were observed in the HFD group. Surprisingly, SCPE administration significantly attenuated the increase of TC and TG contents in liver with a dose-effect relationship ($p < 0.05$). Treatment with 15.72 g/kg BW of SCPE could completely inhibit the increase of TC content in liver induced by HFD. There was no difference between the LFD and HFD + HE groups ($p > 0.05$). SCPE administration at doses of 7.86 and 15.72 g/kg BW decreased TG contents in liver by 20.1% and 35.1% compared with the HFD group ($p < 0.05$).




Figure 2. Effects of SCPE on the contents of TC in serum (A), TG and LDL-C in serum (B), TC and TG in liver (C). Different lower-case letters correspond to significant differences at $p < 0.05$.

3.4. Effects of SCPE on Liver Damage, Oxidative Stress, Inflammation and NAFLD Formation

Serum aminotransferase is usually used to assess hepatitis [31]. In this study, as shown in Figure 3A, ALT activity was significantly increased by HFD ($p < 0.05$). ALT activity in the HFD group was 28.15 U/L, 1.66 times that of the LFD group. SCPE at 7.86 and 15.72 g/kg BW could mitigate the increase of ALT activity induced by HFD ($p < 0.05$). More importantly, administration with 15.72 g/kg BW of SCPE could completely counteract the increase of ALT activity. There was no difference between the LFD group and the HFD + HE group ($p > 0.05$). Serum AST activities were not different between all mice ($p > 0.05$).

A previous study reported that oxidative stress occurs in obesity and NAFLD induced by HFD [32]. Therefore, hepatic oxidative stress was determined, and the results are shown in Figure 3B–D. A 21.5% decrease of SOD activity and a 26.5% decrease of GSH-Px activity were observed in the HFD group compared with the LFD group ($p < 0.05$). However, administration of 7.86 and 15.72 g/kg BW of SCPE for 8 weeks completely inhibited the HFD-induced decrease in GSH-Px activity. Treatment with

15.72 g/kg BW SCPE significantly increased the SOD activity compared with the HFD group ($p < 0.05$). MDA, a product of lipid peroxidation, was measured in this study. An 87.5% increase of MDA content in liver of HFD mice (model group) was observed compared with LFD mice (control) ($p < 0.05$). Importantly, administration with SCPE completely inhibited MDA production compared with the HFD group ($p < 0.05$). A diponectin associated with the metabolism of hepatic lipid [32] was determined in this study. As shown in Figure 3E, hepatic adiponectin content was markedly decreased by HFD, showing about a 45.96% decline compared with the LFD group ($p < 0.05$). Compared with the HFD group, SCPE consumption at doses of 7.86 and 15.72 g/kg BW helped to increase the hepatic adiponectin secretion by 46.13% and 75.86%, respectively ($p < 0.05$).




Figure 3. Effects of SCPE on serum ALT and AST activities (A), hepatic SOD activity (B), GSH-Px (C), MDA (D) and adiponectin (E) content. Different lower-case letters correspond to significant differences at $p < 0.05$.

Serum inflammatory cytokine IL-6 and TNF- α were determined by ELISA kits, and the results are shown in Figure 4A,B. Compared to the LFD group, HFD induced a 16.3% increase of IL-6 level and a 30.4% increase of TNF- α level ($p < 0.05$). Meanwhile, 7.86 and 15.72 g/kg BW of SCPE consumption induced a 25.9% and 33.0% decrease of IL-6 level, 21.2% and 15.2% decrease of TNF- α level compared with the HFD group, respectively ($p < 0.05$).

Q-PCR analysis was performed to evaluate the expression of IL-1 β , TNF- α , NF- κ B and iNOS in the liver (Figure 4C). Mice fed with HFD showed significant increases in TNF- α , IL-1 β , NF- κ B and iNOS levels compared with LFD mice. SCPE consumption at 7.86 and 15.72 g/kg BW significantly inhibited the expression levels of TNF- α , NF- κ B and iNOS ($p < 0.05$). The increase of the expression

level of IL-1 β wasn't inhibited by 7.86 g/kg BW of SCPE consumption. However, 15.72 g/kg BW of SCPE consumption reduced the IL-1 β expression by 35.67% compared to the HFD group ($p < 0.05$).




Figure 4. Effects of SCPE on the levels of serum IL-6 (A), TNF- α (B), inflammation-related genes in liver (C), fatty liver-related genes (D), and H&E staining of adipose (E) (200 $\times$) and liver tissue (F) (200 $\times$ magnification). Different lower-case letters correspond to significant differences at $p < 0.05$.

LXR- α , SREBP-1c and FAS play important roles in lipogenesis and the formation of NAFLD [33]; therefore, these genes were monitored in this study. In the HFD group, LXR- α , SREBP-1c and FAS gene expressions were all at significantly higher levels compared to those in the LFD group ($p < 0.05$, Figure 4D). Surprisingly, administration of SCPE at 7.86 and 15.72 g/kg BW significantly inhibited the expression of these genes ($p < 0.05$), whereby 15.72 g/kg BW of SCPE consumption inhibited LXR- α , SREBP-1c and FAS gene expression by 31.65%, 63.59%, 77.77%, respectively.

Morphological analyses of epididymal adipose and liver were conducted, and the results are shown in Figure 4E,F. The adipocytes of the HFD group were bigger than the LFD group. In addition, administration of SCPE inhibited the increase of adipocytes induced by HFD. As shown in Figure 4F, LFD-fed mice showed normal hepatic tissue with regular morphology of hepatic cells. After a 16-week HFD feeding, serious fatty liver disease occurred, manifesting as macrovesicular steatosis, cell ballooning degeneration and even hepatic parenchyma reticularis. Administration of SCPE effectively reversed the pathological changes induced by HFD in dose-effect relation. In HFD + LE group,

few large lipid vacuoles were observed, and small vacuoles still existed in several hepatic cells. In the pathological section from the HFD+HE group mice, a few small vacuoles were observed. This was nearly same as for the LFD group.

3.5. SCPE Consumption Modulates Gut Microbiota in Obese Mice

Pyrosequencing of variable region V3-V4 of bacterial 16S rRNA genes was carried out in this study to evaluate the impact of SCPE on mice gut microbiota. We produced a total of 585,256 sequences, with an average of 47,249 sequences in LFD group, 44,504 sequences in the HFD group, and 45,772 (HFD+LE) and 33,252 (HFD+HE) sequences in the SCPE groups, respectively. These sequences had a length of 420–450 base pairs (Figure 5I). As shown in the Venn diagram (Figure 5II), the qualified sequences ($>0.001\%$) were clustered into 6143 bacterial OTUs and 841 same OTUs were identified in LFD and HFD groups, 1062 same OTUs were found in LFD and HFD + LE groups, and 1028 same OTUs were found in LFD and HFD+HE groups. Administration with SCPE increased the same OTUs in LFD mice and HFD mice. The rarefaction curve (Supporting Information Figure S2) showed that the current sequencing depth in each sample was enough for analysis of the gut microbial diversity. The chao1 and Shannon curves showed that the abundance and variety of gut microbiota in all studied mice could be observed, and the following determination and analysis results were reliable.




Figure 5. DNA raw data and comparison of the OTUs in all examined colon contents. I: DNA sequencing number and length; II: Venn diagram for describing the common and unique OTUs. A: LFD; B: HFD; C: HFD + LE; D: HFD + HE. Different lower-case letters correspond to significant differences at $p < 0.05$.

To explore the similarity of gut microbial communities in different groups, Nonmetric Multidimensional Scaling analysis based on UniFrac distance was conducted, and the results are shown in Figure 6I. The distance matrix of different samples described the similarity. Five samples in the LFD group clustered, and samples in the HFD group were far away from the LFD group. This indicated that high-fat diet induced significant gut microbial diversification. SCPE consumption at 15.72 g/kg BW (HFD + HE group) could shift the gut microbiota composition disrupted by HFD. The effect of SCPE on the key community of gut microbiota is shown in Figure 6II. *Bacteroidia*, *Bacteroidetes*, *Bacteroidales* and *S24-7*, etc., were the main communities in the gut of LFD mice. HFD induced a significant effect on the species including *Proteobacteria*, *Deltaproteobacteria*, *Desulfovibrionaceae* and *Desulfovibrionales*, etc. Different doses of SCPE consumption demonstrated a selective enrichment of *Coriobacteriales*, *Coriobacteriia*, *Coriobacteriaceae*, and *Bifidobacterium*, *Bifidobacteriales*, *Bifidobacteriaceae*, respectively. The effect of SCPE treatment on the relative abundance of bacterial at family level is shown in Figure 6III. *Lactobacillaceae*, *S24-7* and *Verrcomicrobiaceae* were the main gut microbiota at the family level, whereby *Lactobacillaceae* were remarkably reduced by HFD, and SCPE attenuated the reduction with a significant dose-effect relationship. To better understand the gut microbial differences among four groups, violin plot and box plot were used in this study (Figure 6IV). The abundance of *Actinobacteria*, *Proteobacteria* and *Pseudomonas* were low in LFD group. However, HFD induced significant increase of those. SCPE consumption could significantly

attenuate the increases compared to HFD group. The abundance of *Lactobacillus*, which is a kind of probiotic, was high in the LFD group. Nevertheless, it was greatly reduced by HFD. Treatment with SCPE could increase the *Lactobacillus* in the colon with a dose-effect relationship. Those gut microbial communities can protect health mainly by regulating the metabolism of carbohydrate, amino acid and energy (Supporting Information Figure S2).





Figure 6. Cont.



IV

Figure 6. SCPE modulated the HFD-disrupted gut microbiota composition. I: unweightedUniFrac NMD analysis. II: the significantly different species in four groups. III: the relative abundance (%) of bacterial at family level in four groups. IV: Highly differentiated OTU at phylum and genus levels in four groups. A: LFD; B: HFD; C: HFD + LE; D: HFD + HE. Different lower-case letters correspond to significant differences at $p < 0.05$.

4. Discussion

Obesity has been a worldwide topic because it is associated with many diseases, including hyperglycemia, cardiovascular disease and metabolic syndrome, which seriously affect people's health [4,32,34]. Obesity induced by high-fat diet (HFD) is accompanied by not only the body weight increase, adipose deposition in liver and other organs [25,35], but also oxidative stress and inflammation increase, such as IL-1 β , TNF- α and iNOS [32]. As expected, the present investigation showed that HFD induced the following: an obvious gain in body weight and liver weight, an increase of fasting blood glucose, elevations of lipid levels in serum and liver, increases of serum ALT activity and hepatic MDA content, a significant upregulation of the expression of IL-1 β , TNF- α , NF- κ B and iNOS, decreases of SOD and GSH-Px activities, inhibition of adiponectin secretion, and upregulation of NAFLD-related gene expression, such as LXR- α , SREBP-1c and FAS. Interestingly, after treatment of obese mice with SCPE for 8 weeks, all of the above variations were alleviated. The results indicate that SCPE can inhibit the obesity induced by HFD and prevent NAFLD.

Usually, obesity accompanied by oxidative stress due to reactive oxygen species (ROS) can be produced during mitochondrial and peroxisomal fatty acid oxidation. Another way to produce ROS is over-consumption of oxygen, which generates ROS in the mitochondrial respiratory chain coupled with oxidative phosphorylation in the mitochondria [32]. When oxidative stress persists for a long time in an obese body, antioxidants can be depleted, and antioxidant enzymes activities can be decreased [36]. In the present study, the activities of SOD and GSH-Px were decreased and MDA content was increased in HFD mice. Administration of SCPE to obese mice for 8 weeks significantly increased the activities of SOD and GSH-Px and decreased the MDA content compared to the HFD group. Additionally, there is a huge amount of fat deposited all over the body in animals with obesity. When deposition of liver fat exceeds 5% of hepatocytes in the absence of significant alcohol intake, NAFLD can be formed [37]. The nuclear receptor LXR- α has been implicated in the regulation of lipogenesis and cholesterol homeostasis [38]. Activation of LXR- α can result in the development of hepatic steatosis, which is mediated by the hepatic lipogenic pathway, primarily through SREBP-1c, causing hepatic steatosis and hyperlipidemia. SREBP-1c regulates the expression of lipogenic gene FAS [39]. Therefore, inhibition of LXR- α expression may be beneficial for the control of NAFLD. Administration of SCPE could significantly inhibit LXR- α , SREBP-1c and FAS gene expression, and offer effective treatment for high fat diet-induced NAFLD.

Studies in recent years have demonstrated that ROS produced during fatty acid oxidation triggers inflammatory pathway involving NF- κ B, TNF- α , IL-6, leading to hepatic inflammation [40–42].

Therefore, steatohepatitis is atypical characteristic of NAFLD. Some NAFLD can develop into fibrosis, and even malignant transformation (hepatocellular carcinoma) [43]. In this study, we observed that HFD mice supplemented with SCPE had decreased liver weight, ameliorated hepatic lipid accumulation, and reduced ALT activity compared to the HFD group. In addition, the increase of serum TNF- α , IL-6 was completely inhibited and the expression of liver inflammation genes was significantly down-regulated after treatment with SCPE for 8 weeks. The inhibitory effect of SCPE on NAFLD was further confirmed by conventional histological assessment of livers and adipocytes.

These antioxidant effects, reducing adiposity and preventing NAFLD should be attributed to the abundant phenolic compound in SCPE, which reaches 102 mg GA/g. To identify the phenolic compound in SCPE, UHPLC-Q-Orbitrap-HRMS was used. Twelve phenolic compounds were identified, in which rutin, kaempferol 3-O-beta-rutinoside and quercetin 3-beta-D-glucoside were flavonoid derivatives. The compounds of No. 8–12 were flavonoids and the others were phenolic acid. Naringenin, rutin and chrysin were the main phenolic compounds in SCPE. All of those phenolic compounds lead to SCPE possessing higher antioxidant capability. The FRAP of SCPE was 297.80 mg Trolox/g, obviously higher than that of the 13 bee pollens from Turkey, which ranged from 11.77 to 105.06 μ mol Trolox/g pollen (equating to 2.94–26.42 mg Trolox/g pollen) [44]. The IC₅₀ of DPPH scavenging activity of SCPE was 0.74 mg/mL, lower than that of water extract (2.36 mg/mL) or methanol extract (1.72 mg/mL) of linder bee pollen [45]. Accordingly, SCPE is rich in phenolic compounds, which can attenuate oxidative stress and inhibit inflammation by scavenging ROS in obese mice. Furthermore, adiponectin, whose expression and secretion are unique to differentiated adipocytes, can regulate energy homeostasis, glucose and lipid metabolism and exert anti-inflammatory action [32]. Liver adiponectin secretion was inhibited by HFD and increased after SCPE consumption, which could be another means by which SCPE can reduce adiposity and prevent NAFLD. Briefly, SCPE rich in phenolic compounds reduces adiposity and prevents NAFLD by scavenging ROS, attenuating oxidative stress, increasing adiponectin secretion and suppressing inflammation in obese mice.

Gut microbiota, a complex ecosystem of trillions of microorganisms, codevelops with the host from birth and depends on the host genome, nutrition and life-style [46]. A balanced gut microbiota composition confers benefits to the host, whereas the disturbance of this microbial composition is associated with chronic metabolic disorder, which is involved in enteritis, obesity, diabetes and so on [47]. Recent studies have put forward a new concept, “three Ps for health”, which declares probiotics, prebiotics and polyphenols to modulate either the composition or metabolic/immunological activity of the host gut microbiota [48]. It promotes polyphenols to the same biological level as prebiotics [49]. In this study, we observed the prebiotic effect of SCPE on gut microbiota in obese mice. The results showed that 15.72 g/kg BW of SCPE significantly changed the gut microbial composition in obese mice, manifesting as a rapid increase of *bifidobacterium* and *bifidobacteriaceae* in SCPE treatment mice (Figure 6II). The abundance of *lactobacillaceae* and *lactobacillus* in obese mice gut ecosystem were remarkably reduced compared to normal mice (Figure 6III,IV), whereas different doses of SCPE consumption increased their abundance with a dose-effect relationship. Both *lactobacillus* and *bifidobacterium* are probiotic bacteria, whose growth and abundance in the gut ecosystem directly influences host health. Phenolic compounds can act as promoting factors of growth, proliferation, or survival for probiotic bacteria, including *lactobacillus* and *bifidobacterium* strains, and therefore, exert prebiotic effects. At the same time, phenolic compounds can inhibit the proliferation of some pathogenic bacteria [50]. As expected, the growth of *pseudomonas* was inhibited by SCPE treatment in this study.

While polyphenols modulate the gut microbial balance by stimulation of the growth of beneficial bacteria and inhibition of pathogen bacteria, gut microbiota plays an important role in the transformation and assimilation of polyphenols [51]. Gut microbiota can hydrolyze glycosides, glucuronides, esters, lactones and carry out ring-cleavage, decarboxylation, demethylation, and dehydroxylation reaction to metabolize the phenolic compounds to easily assimilated bioactive compound that result in affecting the intestinal ecology and influence host health [52,53]. In this

study, rutin (quercetin 3-rhamnosyl (1-6) glucoside) is one of the flavonoid compounds in SCPE, which is only absorbed with difficulty. Rutin could be metabolized and rendered into quercetin when it arrived in the colon and encounters *Lactobacillus* and *Bifidobacterium* strains [54]. Then, quercetin could be degraded by gut microbiota to produce simpler and more easily assimilated compounds after the C-ring breakdown. Once the C-ring breakdown takes place at different positions, different simpler phenolic compounds can be formed, probably including 2-(3-hydroxyphenyl) acetic acid, 2-(3,4-dihydroxyphenyl) acetic acid, 3,4-dihydroxybenzoic acid and phloroglucinol [54]. In this study, we investigated whether SCPE promotes the growth of some probiotics and inhibits the growth of pathogenic bacteria. However, the modulation of the gut microbiota on the degradation of polyphenols in SCPE was not explored, and this will be a focus in the following study.

5. Conclusions

In conclusion, SCPE possessing abundant polyphenols and higher antioxidant activities could attenuate body and liver weight gain, decrease fasting blood glucose, cut down the lipid accumulation in serum and liver, lessen oxidative injury and inflammation in obesity mice. Moreover, SCPE could completely inhibit the formation of NAFLD by inhibition of LXR- α , SREBP-1c and FAS gene expression, and repair high fat diet induced liver damage. Additionally, SCPE modulates the structural alteration of gut microbiota in obesity mice, which could be associated with the polyphenols in SCPE. In particular, SCPE could enhance the relative abundance of *Lactobacillus* and reduce the relative abundance of the pathogenic bacteria. To further elucidate the mechanisms of modulation of SCPE on gut microbiota, studies on the change of microbial membrane and phenolic-derived metabolites should be carried out.

Supplementary Materials: The following are available online at <http://www.mdpi.com/2072-6643/11/2/346/s1>, Figure S1: The structure of phenolic compounds identified in SCPE, Figure S2: Alpha diversity analysis of V3-V4 MiSeq sequencing reads of the 16S rRNA gene in different treated mice. I: Rarefaction curve; II: chao1 curve; III: Shannon curve. A: LFD (mice fed with low fat diet); B: HFD mice (mice fed with high fat diet); C: HFD+LE mice (mice fed with high fat diet and 7.86 g/kg BW of SCPE), D: HFD+HE mice (mice fed with high fat diet and 15.72 g/kg BW of SCPE), Figure S3: Functional prediction of gut microbiota. A: LFD (mice fed with low fat diet); B: HFD mice (mice fed with high fat diet); C: HFD+LE mice (mice fed with high fat diet and 7.86 g/kg BW of SCPE), D: HFD+HE mice (mice fed with high fat diet and 15.72 g/kg BW of SCPE).

Author Contributions: Conceptualization, N.C., W.C.; Methodology, S.C.; Data Curation, X.L.; Writing—Original Draft Preparation, N.C., S.C.; Writing—Review and Editing, H.Z.

Acknowledgments: This work was financially supported by The National Natural Science Foundation of China (No. 31602013 and No. 31272510) and The Agricultural Science and Technology Project of Shaanxi Province (No. 2017NY-073).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Skinner, A.C.; Ravanbakht, S.N.; Skelton, J.A.; Perrin, E.M.; Armstrong, S.C. Prevalence of obesity and severe obesity in US children, 1999–2016. *Pediatrics* **2018**, *141*, e20173459. [CrossRef] [PubMed]
2. Petts, G.; Lloyd, K.; Goldin, R. Fatty liver disease. *Diagn. Histopathol.* **2014**, *20*, 102–108. [CrossRef]
3. Doerstling, S.S.; O’Flanagan, C.H.; Hursting, S.D. Obesity and cancer metabolism: A perspective on interacting tumor—intrinsic and extrinsic factors. *Front. Oncol.* **2017**, *7*, 216. [CrossRef] [PubMed]
4. Zhang, Y.; Zhao, J.; Chu, Z.; Zhou, J. Increasing prevalence of childhood overweight and obesity in a coastal province in China. *Pediatr. Obes.* **2016**, *11*, e22–e26. [CrossRef] [PubMed]
5. Skinner, A.C.; Perrin, E.M.; Skelton, J.A. Prevalence of obesity and severe obesity in US children, 1999–2014. *Obesity* **2016**, *24*, 1116–1123. [CrossRef] [PubMed]
6. Ogden, C.L.; Carroll, M.D.; Lawman, H.G.; Fryar, C.D.; Kruszon-Moran, D.; Kit, B.K.; Flegal, K.M. Trends in obesity prevalence among children and adolescents in the United States, 1988–1994 through 2013–2014. *JAMA* **2016**, *315*, 2292–2299. [CrossRef] [PubMed]
7. Roberts, E.A. Pediatric nonalcoholic fatty liver disease (NAFLD): A “growing” problem? *Hepatology* **2007**, *46*, 1133–1142. [CrossRef]

8. Jurado-Ruiz, E.; Varela, L.M.; Luque, A.; Berná, G.; Cahuana, G.; Martinez-Force, E.; Gallego-durán, R.; Soria, B.; Roos, B.; Gómez, M.R.; et al. An extra virgin olive oil rich diet intervention ameliorates the nonalcoholic steatohepatitis induced by a high-fat “Western-type” diet in mice. *Mol. Nutr. Food Res.* **2017**, *61*, 1600549. [[CrossRef](#)]
9. Wang, D.; Wei, Y.; Pagliassotti, M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. *Endocrinology* **2006**, *147*, 943–951. [[CrossRef](#)]
10. Neuschwander-Tetri, B.A. Non-alcoholic fatty liver disease. *BMC Med.* **2017**, *15*, 45. [[CrossRef](#)]
11. Sadaf, N.; Munazza, S.; Hina, S.; Misbah, M.; Maliha, S. A review of antihyperlipidemic effect of synthetic phenolic compounds. *Matrix Sci. Med.* **2017**, *1*, 22–26.
12. Chen, H.; Sang, S. Biotransformation of tea polyphenols by gut microbiota. *J. Funct. Foods* **2014**, *7*, 26–42. [[CrossRef](#)]
13. Boursier, J.; Mueller, O.; Barret, M.; Machado, M.; Fizanne, L.; Araujo-Perez, F.; Guy, C.D.; Seed, P.C.; Rawls, J.F.; David, L.A.; et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology* **2016**, *63*, 764–775. [[CrossRef](#)] [[PubMed](#)]
14. Chen, G.; Xie, M.; Dai, Z.; Wang, P.; Ye, H.; Zeng, X.; Sun, Y. Kudingcha and Fuzhuan brick tea prevent obesity and modulate gut microbiota in high-fat diet fed mice. *Mol. Nutr. Food Res.* **2018**, *62*, 1700485. [[CrossRef](#)] [[PubMed](#)]
15. Gómez-Juaristi, M.; Martínez-López, S.; Sarria, B.; Bravo, L.; Mateos, R. Absorption and metabolism of yerba mate phenolic compounds in humans. *Food Chem.* **2018**, *240*, 1028–1038. [[CrossRef](#)] [[PubMed](#)]
16. Liu, Z.; Chen, Z.; Guo, H.; He, D.; Zhao, D.; Wang, Z.; Zhang, W.; Liao, L.; Zhang, C.; Ni, L. The modulatory effect of infusions of green tea, oolong tea, and black tea on gut microbiota in high-fat-induced obese mice. *Food Funct.* **2016**, *7*, 4869–4879. [[CrossRef](#)]
17. Neyrinck, A.M.; Héu, V.F.V.; Bindels, L.B.; Backer, F.D.; Cani, P.D.; Delzenne, N.M. Polyphenol-rich extract of pomegranate peel alleviates tissue inflammation and hypercholesterolaemia in high-fat diet-induced obese mice: Potential implication of the gut microbiota. *Br. J. Nutr.* **2013**, *109*, 802–809. [[CrossRef](#)]
18. Baldwin, J.; Collins, B.; Wolf, P.G.; Martinez, K.; Shen, W.; Chuang, C.; Zhong, W.; Cooney, P.; Cockrell, C.; Chang, E.; et al. Table grape consumption reduces adiposity and markers of hepatic lipogenesis and alters gut microbiota in butter fat-fed mice. *J. Nutr. Biochem.* **2016**, *27*, 123–135. [[CrossRef](#)]
19. Su, D.; Zhang, R.; Hou, F.; Chi, J.; Huang, F.; Yan, S.; Liu, L.; Deng, Y.; Wei, Z.; Zhang, M. Lychee pulp phenolics ameliorate hepatic lipid accumulation by reducing miR-33 and miR-122 expression in mice fed a high-fat diet. *Food Funct.* **2017**, *8*, 808–815. [[CrossRef](#)]
20. Ai, J.; Wang, Y.P.; Li, C.Y.; Yan, T.L.; Guo, X.W. Pollen shape and pollination character of *Schisandrachinensis*. *J. Jilin Agric. Univ.* **2007**, *29*, 293–297.
21. Sun, C.R. Pollen morphology of the *Schisandraceae* and its systematic significance. *ActaPhytotax. Sin.* **2000**, *38*, 437–445.
22. Cheng, N.; Ren, N.; Gao, H.; Lei, X.; Zheng, J.; Cao, W. Antioxidant and hepatoprotective effects of *Schisandrachinensis* pollen extract on CCl₄-induced acute liver damage in mice. *Food Chem. Toxicol.* **2013**, *55*, 234–240. [[CrossRef](#)] [[PubMed](#)]
23. Brand-Williams, W.; Cuvelier, M.E.; Berset, C.L.W.T. Use of a free radical method to evaluate antioxidant activity. *LWT-Food Sci. Technol.* **1995**, *28*, 25–30. [[CrossRef](#)]
24. Benzie, F.F.; Strain, J.J. The ferric reducing ability of plasma as a measure of “antioxidant power”: The FRAP assay. *Anal. Biochem.* **1996**, *239*, 70–76. [[CrossRef](#)] [[PubMed](#)]
25. Singh, N.; Rajini, P.S. Free radical scavenging activity of an aqueous extract of potato peel. *Food Chem.* **2004**, *85*, 611–616. [[CrossRef](#)]
26. Wu, T.; Yin, J.; Zhang, G.; Long, H.; Zheng, X. Mulberry and cherry anthocyanin consumption prevents oxidative stress and inflammation in diet-induced obese mice. *Mol. Nutr. Food Res.* **2016**, *60*, 687–694. [[CrossRef](#)] [[PubMed](#)]
27. Sim, W.; Park, S.; Lee, K.; Je, Y.; Yin, H.; Choi, Y.; Sung, S.H.; Park, S.; Park, H.; Shin, K.J.; et al. LXR- α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver. *Biochem. Pharmacol.* **2014**, *90*, 414–424. [[CrossRef](#)]
28. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_t}$ method. *Methods* **2001**, *25*, 402–408. [[CrossRef](#)]

29. Liu, G.; Bei, J.; Liang, L.; Yu, G.; Li, L.; Li, Q. Stachyose improves inflammation through modulating gut microbiota of high-fat diet/streptozotocin-induced type 2 diabetes in rats. *Mol. Nutr. Food Res.* **2018**, *62*, 1700954. [[CrossRef](#)]
30. Caporaso, J.G.; Kuczynski, J.J.; Stombaugh, K.; Bittinger, F.D.; Bushman, E.K.; Costello, N. QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* **2010**, *7*, 335–336. [[CrossRef](#)]
31. Shim, J.J.; Kim, J.W.; Oh, C.H.; Lee, Y.R.; Lee, J.S.; Park, S.Y.; Kim, B.H.; Oh, I.H. Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B: A large national cohort study. *Liver Int.* **2018**, *38*, 1751–1759. [[CrossRef](#)] [[PubMed](#)]
32. Fernández-Sánchez, A.; Madrigal-Santillán, E.; Bautista, M.; Esquivel-Soto, J.; Morales-González, Á.; Esquivel-Chirino, C.; Durante-Montiel, I.; Sánchez-Rivera, G.; Valadez-Vega, C.; Morales-González, J.A. Inflammation, oxidative stress, and obesity. *Int. J. Mol. Sci.* **2011**, *12*, 3117–3132.
33. Chen, Q.; Wang, T.; Li, J.; Wang, S.; Qiu, F.; Yu, H.; Zhang, Y.; Wang, T. Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD). *Nutrients* **2017**, *9*, 96. [[CrossRef](#)] [[PubMed](#)]
34. Dandona, P.; Aljada, A.; Bandyopadhyay, A. Inflammation: The link between insulin resistance, obesity and diabetes. *Trends Immunol.* **2004**, *25*, 4–7. [[CrossRef](#)]
35. Zhang, X.; Zhang, M.; Ho, C.; Guo, X.; Wu, Z.; Weng, P.; Yan, M. Metagenomics analysis of gut microbiota modulatory effect of green tea polyphenols by high fat diet-induced obesity mice model. *Funct. Foods* **2018**, *46*, 268–277. [[CrossRef](#)]
36. Amirkhizi, F.; Siassi, F.; Minaie, S.; Djalali, M.; Rahimi, A.; Chamari, M. Is obesity associated with increased plasma lipid peroxidación and oxidative stress in women. *Arya Atheroscler.* **2007**, *2*, 189–192.
37. Neuschwander-Tetri, B.A.; Caldwell, S.H. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. *Hepatology* **2003**, *37*, 1202–1219. [[CrossRef](#)] [[PubMed](#)]
38. Lin, Y.; Wang, C.C.N.; Chang, H.; Chu, F.; Hsu, Y.; Cheng, W.; Ma, W.; Chen, C.; Wan, L.; Lim, Y. Ursolic acid, a novel liver X receptor α (LXR α) antagonist inhibiting ligand-induced nonalcoholic fatty liver and drug-induced lipogenesis. *J. Agric. Food Chem.* **2018**, *66*, 11647–11662. [[CrossRef](#)]
39. Higuchi, N.; Kato, M.; Shundo, Y.; Tajiri, H.; Tanaka, M.; Yamashita, N.; Kohjima, M.; Kotoh, K.; Nakamuta, M.; Takayanagi, R.; et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. *Hepatol. Res.* **2008**, *38*, 1122–1129. [[CrossRef](#)]
40. Sikaris, K. The clinical biochemistry of obesity. *Clin. Biochem. Rev.* **2004**, *25*, 165–181.
41. Fonseca-Alaniz, M.H.; Takada, J.; Alonso-Vale, M.I.; Lima, F.B. Adipose tissue as an endocrine organ: From theory to practice. *J. Pediatr.* **2007**, *83*, S192–S203. [[CrossRef](#)]
42. Alwahsh, S.M.; Xu, M.; Schultze, F.C.; Wilting, J.; Mihm, S.; Raddatz, D.; Ramadori, G. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. *PLoS ONE* **2014**, *9*, e104220. [[CrossRef](#)] [[PubMed](#)]
43. Stender, S.; Kozlitina, J.; Nordestgaard, B.G.; Tybjaerg-Hansen, A.; Hobbs, H.H.; Cohen, J.C. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. *Nat. Genet.* **2017**, *49*, 842–847. [[CrossRef](#)] [[PubMed](#)]
44. Ulusoy, E.; Kolayli, S. Phenolic composition and antioxidant properties of anzer bee pollen. *J. Food Biochem.* **2014**, *38*, 73–82. [[CrossRef](#)]
45. Jin, T.; Saravanakumar, K.; Wang, M. In vitro and in vivo antioxidant properties of water and methanol extracts of linden bee pollen. *Biocatal. Agric. Biotech.* **2018**, *13*, 186–189. [[CrossRef](#)]
46. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. *Science* **2012**, *336*, 1262–1267. [[CrossRef](#)] [[PubMed](#)]
47. Vaiserman, A.M.; Koliada, A.K.; Marotta, F. Gut microbiota: A player in aging and a target for anti-aging intervention. *Ageing Res. Rev.* **2017**, *35*, 36–45. [[CrossRef](#)]
48. Espín, J.C.; González-Sarrias, A.; Tomás-Barberán, F.A. The gut microbiota: A key factor in the therapeutic effects of (poly)phenols. *Biochem. Pharmacol.* **2017**, *139*, 82–93. [[CrossRef](#)]
49. Marchesi, J.R.; Adams, D.H.; Fava, F.; Hermes, G.D.A.; Hirschfield, G.M.; Hold, G.; Quraishi, M.N.; Kinross, J.; Smidt, H.; Tuohy, K.M.; et al. Hart, The gut microbiota and host health: A new clinical frontier. *Gut* **2016**, *65*, 330–339. [[CrossRef](#)]
50. Hervet-Hernández, D.; Goñi, I. Dietary polyphenols and human gut microbiota: A review. *Food Rev. Int.* **2011**, *27*, 154–169. [[CrossRef](#)]
51. Cardona, F.; Andrés-Lacueva, C.; Tulipani, S.; Tinahones, F.J.; Queipo-Ortuño, M. Benefits of polyphenols on gut microbiota and implications in human health. *J. Nutr. Biochem.* **2013**, *24*, 1415–1422. [[CrossRef](#)] [[PubMed](#)]

52. Aura, A.M. Microbial metabolism of dietary phenolic compounds in the colon. *Phytochem. Rev.* **2008**, *7*, 407–429. [[CrossRef](#)]
53. Rechner, A.R.; Smith, M.A.; Kuhnle, G.; Gibson, G.R.; Debnam, E.S.; Srai, S.K.S.; Moore, K.P.; Rice-Evans, C.A. Colonic metabolism of dietary polyphenol: Influence of structure on microbial fermentation products. *Free Radic. Biol.* **2004**, *36*, 212–225. [[CrossRef](#)]
54. Selma, M.A.; Espín, J.C.; Tomás-Barberán, F.A. Interaction between phenolics and gut microbiota: Role in human health. *J. Agric. Food Chem.* **2009**, *57*, 6485–6501. [[CrossRef](#)] [[PubMed](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).